[EN] SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF<br/>[FR] 5-AMINOPYRAZOLES SUBSTITUÉS ET LEUR UTILISATION
申请人:BAYER SCHERING PHARMA AG
公开号:WO2010020363A1
公开(公告)日:2010-02-25
The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.
6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines
申请人:Hendrix Martin
公开号:US20070105876A1
公开(公告)日:2007-05-10
The invention relates to novel 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.
Acid‐Mediated Three Component Assembly of 4‐Fluoropyrazoles from α‐Fluoronitroalkenes, Hydrazines, and Aldehydes
作者:Vladimir A. Motornov、Andrey A. Tabolin、Yulia V. Nelyubina、Valentine G. Nenajdenko、Sema L. Ioffe
DOI:10.1002/ejoc.202000841
日期:2020.8.31
Three‐component one pot assembly of 4‐fluoropyrazoles is described. The method involves formal oxidative [3+2]‐annulation between elusive fluoroalkynes and azomethine imines.
[DE] 6-CYCLYLMETHYL- UND 6-ALKYLMETHYL-SUBSTITUIERTE PYRAZOLOPYRIMIDINE<br/>[EN] 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES<br/>[FR] PYRAZOLOPYRIMIDINES SUBSTITUEES PAR 6-CYCLYLMETHYLE ET 6-ALKYLMETHYLE
申请人:BAYER HEALTHCARE AG
公开号:WO2004099211A1
公开(公告)日:2004-11-18
Die Erfindung betrifft neue 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung zur Herstellung von Arzneimitteln zur Verbesserung von Wahrnehmung, Konzentrationsleistung, Lern- und/oder Gedächtnisleistung. (Formel (I))
Design of peptidomimetic .delta. opioid receptor antagonists using the message-address concept
作者:P. S. Portoghese、M. Sultana、A. E. Takemori
DOI:10.1021/jm00168a028
日期:1990.6
Highly selective nonpeptide ligands with potent deltaopioidreceptorantagonist activity have been developed using the message-addressconcept. This approach envisaged the deltaopioidreceptor to contain two major recognition subsites; a message subsite which recognizes the pharmacophore, and an address subsite that is unique for the deltareceptor type and confers selectivity. The message and address